Top Story

Venetoclax combination improves PFS in refractory chronic lymphotropic leukemia

Venetoclax combination improves PFS in refractory chronic lymphotropic leukemia
December 13, 2017

Read the Perspective from Matthew S. Davids, MD, MMSc

ATLANTA — Patients with relapsed or refractory chronic lymphotropic leukemia showed improved PFS 2 years after receiving venetoclax plus rituximab compared with patients treated with bendamustine plus rituximab, according to results from the MURANO clinical trial presented during the late-breaking abstract session of the ASH Annual Meeting and Exposition.

“When we developed this trial, the standard of care in many jurisdictions was chemotherapy together with a monoclonal antibody, the most common being a combination of bendamustine and rituximab [Rituxan; Genentech, Biogen]. Previous studies had shown we would expect approximately a 60% response rate, and the average PFS would be around 15 months,” John Seymour, MD, director of Peter MacCallum Cancer Centre in Melbourne, Australia, and lead investigator of the MURANO trial, said during a press conference. “Venetoclax [Venclexta; AbbVie, Genentech] is an orally administered and very specific and selective inhibitor of BCL-2. As a single agent, it’s shown very high activity, including among patients with poor prognostic factors.”

Policy brief: Trump administration actions threaten access for LGBT patients

December 13, 2017
Lesbian, gay, bisexual and transgender adults are likely to encounter increased discrimination as they try to access health care services after a series of actions…
Meeting NewsPerspective

Maintenance rituximab improves PFS in follicular lymphoma

December 13, 2017
ATLANTA — Maintenance rituximab following first-line bendamustine and rituximab significantly improved PFS, with a trend toward improved OS, among patients with
In the Journals Plus

Early integrated palliative care improves coping strategies for patients with incurable cancer

December 13, 2017
Patients with terminal cancer who underwent early integration of oncology and palliative care made greater use of approach-oriented coping strategies compared with those
In the Journals

Coffee may improve survival in colon cancer

December 13, 2017
Patients with colorectal cancer who drank coffee, either caffeinated or decaffeinated, showed a lower risk for colorectal cancer-specific death and overall death in two…
More Headlines »

The Identification and Management of Immune-related Adverse Events in Patients with Cancer: Practice Essentials for Emergency Medicine Providers

This activity is supported by an educational grant from Bristol-Myers Squibb.

The incorporation of immunotherapies, especially the immune checkpoint inhibitors, into treatment regimens for patients…
More »
Meeting News

VIDEO: Letermovir CMV prophylaxis offers survival benefit in hematopoietic cell transplant patients

October 14, 2017
More »
Resource Centers
San Antonio Breast Cancer Symposium

San Antonio Breast Cancer Symposium


Ace the Case: A 48-Year-Old Female Diagnosed With Polycythemia Vera (PV) 7 Years Ago

There is no commercial support for this activity.

This CME case study will discuss the treatment of polycythemia rubra vera.
More »
Current Issues
View the Current Issue
HemOnc Today